Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment

被引：0
|
作者：
Martorell, C. [3 ]
Ward, D. [2 ]
Short, W. S. [4 ]
Ramgopal, M. [5 ]
Das, M. [1 ]
Nguyen-Cleary, T. [1 ]
Shave, A. [1 ]
McCallister, S. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] DuPont Circle Phys, Washington, DC USA
[3] Res Inst, Springfield, MA USA
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Midway Immunol & Res Ctr, Ft Pierce, FL USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2017年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
C86
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [41] Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
    Natukunda, Eva
    Gaur, Aditya H.
    Kosalaraksa, Pope
    Batra, Jagmohan
    Rakhmanina, Natella
    Porter, Danielle
    Shao, Yongwu
    Zhang, Heather
    Pikora, Cheryl
    Rhee, Martin S.
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (01): : 27 - 34
  • [42] An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy (vol 11, e0155406, 2016)
    Llibre, Josep M.
    Raffi, Francois
    Moyle, Graeme
    Behrens, Georg
    Bouee, Stephane
    Reilly, Geraldine
    Borg, Peter
    Piontkowsky, David
    Rogatto, Felipe
    [J]. PLOS ONE, 2016, 11 (07):
  • [43] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [44] Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
    Orkin, C.
    Eron, J.
    Rockstroh, J.
    Podzamczer, D.
    Esser, S.
    Vandekerckhove, L.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [45] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-naive (AMBER) and virologically suppressed (EMERALD) patients with neurologic and/or psychiatric comorbidities: Week 96 subgroup analysis
    Bushen, J.
    Luo, D.
    Simonson, R. B.
    Burress, R.
    Brown, K.
    Anderson, D.
    Dunn, K.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 111 - 112
  • [46] Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir combinations in HIV-1 adult population: A systematic review and meta-analysis
    Biju, Anto Amith J.
    Shaju, Aina
    Mudigubba, Manoj Kumar
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 325 - 326
  • [47] Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
    Dunn, Keith
    Baugh, Bryan
    Bejou, Nika
    Luo, Donghan
    Campbell, Jennifer
    Seyedkazemi, Sareh
    Anderson, David
    [J]. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2022, 21
  • [48] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
    Post, Frank A.
    Tebas, Pablo
    Clarke, Amanda
    Cotte, Laurent
    Short, William R.
    Abram, Michael E.
    Jiang, Shuping
    Cheng, Andrew
    Das, Moupali
    Fordyce, Marshall W.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 180 - 184
  • [49] Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF
    Anthony Mills
    Will Garner
    Anton Pozniak
    Juan Berenguer
    Rebecca M. Speck
    Randall Bender
    Thai Nguyen
    [J]. The Patient - Patient-Centered Outcomes Research, 2015, 8 : 359 - 371
  • [50] Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
    Gaur, Aditya H.
    Kizito, Hilda
    Prasitsueubsai, Wasana
    Rakhmanina, Natella
    Rassool, Mohammed
    Chakraborty, Rana
    Batra, Jagmohan
    Kosalaraksa, Pope
    Luesomboon, Wicharn
    Porter, Danielle
    Shao, Yongwu
    Myers, Michael
    Ting, Lillian
    SenGupta, Devi
    Quirk, Erin
    Rhee, Martin S.
    [J]. LANCET HIV, 2016, 3 (12): : E561 - E568
12345